New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2013
10:10 EDTROSGRosetta Genomics surges after announcing study publication
Shares of Rosetta Genomics (ROSG), which develops and commercializes microRNA-based molecular diagnostics, advanced in early trading after the company announced the recent publication of data from a study assessing the differences between cancer of unknown primary, or CUP, and metastatic solid tumors of known primary metastases, or KPM, by profiling microRNA expression. According to the company's press release, the study's author, George Pentheroudakis, said, "This research is the first look for microRNA characteristics of CUP tumors. Study results confirmed epidemiologic evidence suggesting that patients with favorable prognosis CUP have a presentation, response to therapy and outcome no different from metastatic tumors of matched primaries." The company's CEO said, "This publication demonstrates the utility of microRNA profiling in understanding the biology of CUP and may have important implications for the prognosis and treatment of CUP patients," adding that the company looks forward to the publication of the full data set. The company offered a link to an abstract of the study, which had an e-publication date of Nov. 4, 2012 ahead of its print publication, according to the post on the site of the U.S. National Library of Medicine and National Institutes of Health. In early morning trading, Rosetta Genomics shares rose $1.02, or 22.05% to $5.62. Reference Link
News For ROSG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 8, 2015
07:24 EDTROSGAegis to hold a conference
Subscribe for More Information
September 30, 2015
09:18 EDTROSGRosetta Genomics announces partnership with FNApath
Rosetta Genomics announces that the company has reached an agreement-in-principle with FNApath of Little Rock, Arkansas, under which Rosetta Genomics will provide endocrinologists initially testing their patients for thyroid cancer with the option of using a pathologist or laboratory of their own choosing, or FNApath, a centralized laboratory with an expertise in diagnosing thyroid cancer. In the event of an indeterminate result, the sample would then be tested with RosettaGx Thyroid Reveal, the company's thyroid neoplasia assay for the differential diagnosis of indeterminate fine needle aspirates, or FNAs.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use